Deucravacitinib

BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. BMS-986165 inhibits IL-12/23 and type I IFN pathways.


Cat. No.: EX-A3154	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	385	In-stock
250mg	585	In-stock
500mg	785	In-stock
1g	1185	In-stock
5g	3560	In-stock
10g	5450	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	BMS-986165
CAS No.	1609392-27-9
Purity	>98%
Formula	C20H22N8O3
Mol Weight	425.459
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18. [2]. Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017;76:859.
CoA	CoA of Deucravacitinib

Smiles:	O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]


		Search